Orphazyme is in dialog with a number of potential suitors in search of rescue

Biotech company Orphazyme is in need of a lifeline, and its deputy chair, Bo Jesper Hansen, is in talks with five to ten potential buyers and investors as a part of current restructuring plans.
Bo Jesper Hansen, deputy chair of the board at Orphazyme | Photo: Kåre Viemose
Bo Jesper Hansen, deputy chair of the board at Orphazyme | Photo: Kåre Viemose
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

On Thursday, Orphazyme released its restructuring plan, stating that potential investors and buyers had already been identified and contacted.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading